<DOC>
	<DOCNO>NCT01536665</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate liraglutide adjunct insulin treatment change glucagon response hypoglycaemia subject type 1 diabetes compare conventional insulin treatment 4 week ' treatment liraglutide placebo . Subjects initially randomise one three dose group , subsequently randomly allocate one two treatment sequence ( liraglutide/placebo placebo/liraglutide ) .</brief_summary>
	<brief_title>The Effect Liraglutide Adjunct Insulin Glucagon Response Hypoglycaemia Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month prior randomisation Body mass index ( BMI ) 20.0 28.0 kg/m^2 ( inclusive ) Use liraglutide exenatide within 3 month randomisation Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge trial physician hospitalisation diabetic ketoacidosis previous 6 month Subject donate blood plasma past month 500 mL within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>